This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): Belatacept, LEA29Y, BMS-224818
Description: Belatacept (LEA29Y), a selective costimulationblocker, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4. Belatacept was derived from abatacept (Orencia),with only a two amino acid difference. This gives it greater binding affinity for the CD80 and CD86 costimulatory ligands of antigen-presenting cells.
In the context of antigen recognition (signal 1), the interaction of CD80 and CD86 with the surface costimulatory receptor CD28 of T cells(signal 2) is required for full activation of T cells. Blockade of signal 2 inhibitsT-cell activation, promoting anergy and apoptosis.
Additional information available to subscribers only: